Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tianhu Capsule is a Traditional Chinese Medicine (TCM) formulation developed by Sichuan Lele Pharmaceutical Technology Development Co., Ltd. for the treatment of benign prostatic hyperplasia (BPH) and chronic prostatitis. The medication is composed of several herbal ingredients, including *Polygonum cuspidatum* (Huzhang) and *Semiaquilegia adoxoides* (Tiankuizi), which are traditionally used to clear heat, resolve dampness, and dissipate nodules. Pharmacological studies indicate that Tianhu Capsule works by inhibiting the expression of growth factors such as transforming growth factor-beta 1 (TGF-β1) and basic fibroblast growth factor (bFGF) in prostate tissue, which are key drivers of stromal and epithelial cell proliferation. By modulating these pathways, the drug helps reduce prostate volume and alleviate lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, and weak stream. It is approved in China as a Chinese Patent Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tianhu Capsule.